If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Astra Zeneca
Details (Indentifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sponsors: Astra Zeneca
Details (Indentifier #): NCT04964934
Title: EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT04092283
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT02339571
Title: EA6194, Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT04708418
Title: Evaluation of clinical use of Effortless Oxygen device in patients with oxygen dependence
Department: Pulmonary
Diagnosis: Lung - COPD
Sponsors: Effortless
Details (Indentifier #): NA
Title: FRNM-008 The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Freenome
Details (Indentifier #): NCT05254834
Title: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
Details (Indentifier #): NCT05710328
Title: LIBREXIA-AF A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Edo Kaluski, MD, FACC, FESC, FSCAI
Sponsors: Janssen
Details (Indentifier #): NCT05757869
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Thomas J McDonald, MD
Sub-Investigator(s):
Sponsors: Janssen
Details (Indentifier #): none
Showing 11-20 of 41 Results